2022 Annual Meeting - Difficult Cases in Lung SBRT
This is an education session focused on difficult cases in the use of lung SBRT. It will include a set of challenging cases followed by a short didactic session on each challenging topic. The cases/topics will include: 1) SBRT for a large (>5 cm) primary, node negative tumor. This case will address the use of adjuvant systemic therapy and safe delivery of SBRT for large tumors. 2) SBRT for an ultracentral lung tumor. This case will address patient selection, risk/benefit analysis, dose constraints and expected outcomes when using SBRT for an ultracentral lung cancer. 3) SBRT in a patient with interstitial lung disease. This case will address risks, benefits and alternatives to SBRT for ILD patients with lung cancer.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, radiation physicists, radiation therapists and radiation oncology residents.
Upon completion of this activity, participants should be able to:
- Describe the appropriate use of lung SBRT in challenging clinical scenarios.
- Appropriately assess complex patients for lung SBRT and discuss the risks and benefits of lung SBRT with these patients.
Megan Daly, MD is employed at University of California Davis Comprehensive Cancer Center, Sacramento, CA and receives compensation/remuneration/funding from Genentech, Merck, EMD Serono.
Meredith Giuliani, MD is employed at Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, ON, Canada and receives compensation/remuneration/funding from Elekta Inc., Eli Lilly.
Jeremy Harris, MD is employed at Department of Radiation Oncology, University of California - Irvine, Orange, CA and has no financial relationships with a commercial interest
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.